Core Viewpoint - Four Seasons Pharmaceutical (00460.HK) has received approval from the National Medical Products Administration for six new specifications of its self-developed polylactic acid facial filler, known as "童颜针" (Youthful Needle), marking a significant advancement in the company's market positioning within the regenerative aesthetic medicine sector [1] Group 1: Product Development - The newly approved specifications include 60mg, 80mg, 100mg, 110mg, 120mg, and 130mg bottles, which will enhance the product selection spectrum [1] - Prior to this expansion, the product had already been approved in three specifications: 45mg, 75mg, and 150mg bottles, catering to different needs such as preventive management, combination therapy, and comprehensive rejuvenation [1] Group 2: Competitive Advantage - Four Seasons Pharmaceutical is the only company in China that holds compliant regenerative filler products, specifically "少女针" (Girl Needle) and "童颜针" (Youthful Needle), along with three other major medical aesthetic devices: botulinum toxin, hydrating injections, and golden micro-needles [1] - The Youthful Needle utilizes a core component of L-lactic acid (PLLA) microspheres, achieving dual effects of "immediate filling + long-lasting regeneration," with patented technology ensuring uniform microsphere morphology and particle size, demonstrating excellent safety and clinical efficacy [1]
四环医药(00460.HK)童颜针新增规格获国家药监局批准上市